About this Research Topic
Given the success of Research Topic New Mechanisms and Drugs for the Treatment of Cardiovascular Disease with Diabetes and the rapidly evolving subject area, we are pleased to announce the launch of Volume II.
The intersection of cardiovascular disease and diabetes represents a critical area of medical research, given the increasing prevalence of diabetes worldwide. From 150 million individuals in 2000 to 400 million in 2017, the number of people living with diabetes continues to rise, significantly impacting the global burden of cardiovascular diseases. Cardiovascular complications, particularly myocardial infarction, remain the leading cause of mortality among individuals with diabetes mellitus. The pathophysiology of diabetes, characterized by inflammation and oxidative stress, contributes to the risk factors for cardiovascular disease development. Recent studies have highlighted the cardiovascular benefits of new drugs such as sodium/glucose cotransporter-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1a), which are traditionally used for diabetes management. Notably, SGLT2i has shown efficacy in treating heart failure in non-diabetic patients, indicating a broader therapeutic potential. Despite these advancements, there remains a need for further exploration of novel mechanisms and therapeutic targets to enhance treatment strategies for cardiovascular disease in the context of diabetes.
This research topic aims to explore novel therapeutic targets and mechanisms in the treatment of cardiovascular diseases associated with diabetes. We seek to address key questions regarding the efficacy and potential of existing and emerging drugs, such as SGLT2 inhibitors, GLP1a, DPP4 inhibitors, statins, and aspirin, in managing these conditions. By examining both clinical and basic studies, we aim to provide a comprehensive understanding of the therapeutic landscape and future challenges in this field.
To gather further insights in the treatment of cardiovascular disease in the context of diabetes, we welcome articles addressing, but not limited to, the following themes:
- Novel therapeutic targets for cardiovascular disease in diabetes
- Mechanisms of action of existing and emerging drugs
- Clinical and preclinical studies on drug efficacy and safety
- Pathophysiological insights into cardiovascular complications in diabetes
- Advances in pharmacological interventions and their implications
- Comparative studies of drug effects in diabetic versus non-diabetic populations
- Genetic and molecular biology studies related to cardiovascular disease and diabetes.
The intersection of cardiovascular disease and diabetes represents a critical area of medical research, given the increasing prevalence of diabetes worldwide. From 150 million individuals in 2000 to 400 million in 2017, the number of people living with diabetes continues to rise, significantly impacting the global burden of cardiovascular diseases. Cardiovascular complications, particularly myocardial infarction, remain the leading cause of mortality among individuals with diabetes mellitus. The pathophysiology of diabetes, characterized by inflammation and oxidative stress, contributes to the risk factors for cardiovascular disease development. Recent studies have highlighted the cardiovascular benefits of new drugs such as sodium/glucose cotransporter-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1a), which are traditionally used for diabetes management. Notably, SGLT2i has shown efficacy in treating heart failure in non-diabetic patients, indicating a broader therapeutic potential. Despite these advancements, there remains a need for further exploration of novel mechanisms and therapeutic targets to enhance treatment strategies for cardiovascular disease in the context of diabetes.
This research topic aims to explore novel therapeutic targets and mechanisms in the treatment of cardiovascular diseases associated with diabetes. We seek to address key questions regarding the efficacy and potential of existing and emerging drugs, such as SGLT2 inhibitors, GLP1a, DPP4 inhibitors, statins, and aspirin, in managing these conditions. By examining both clinical and basic studies, we aim to provide a comprehensive understanding of the therapeutic landscape and future challenges in this field.
To gather further insights in the treatment of cardiovascular disease in the context of diabetes, we welcome articles addressing, but not limited to, the following themes:
- Novel therapeutic targets for cardiovascular disease in diabetes
- Mechanisms of action of existing and emerging drugs
- Clinical and preclinical studies on drug efficacy and safety
- Pathophysiological insights into cardiovascular complications in diabetes
- Advances in pharmacological interventions and their implications
- Comparative studies of drug effects in diabetic versus non-diabetic populations
- Genetic and molecular biology studies related to cardiovascular disease and diabetes.
Keywords: Diabetes, Cardiovascular diseases, Mechanisms, Drugs, Cardiovascular therapeutics, Oxidative stress, Inflammation, SGLT2 inhibitors
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
